Food manufacturers face rising demand for nutritious but indulgent smaller portions, with GLP-1 behavioural shifts adding momentum
The rise of GLP-1 receptor agonists such as Mounjaro and Ozempic, combined with the rise of “on-the-go” consumption habits and the “snackification” of meals, has...